Colchicine and Heart Disease: Why This Drug Is Gaining New Attention

Synopsis

Heart disease prevention has long focused on cholesterol, yet many patients on optimal statin therapy still have cardiac events. Chronic inflammation is now recognised as an independent, modifiable risk driver, and colchicine, a centuries-old anti-inflammatory, is proving effective at targeting it.

Key takeaways:

Major trials (LoDoCo, COLCOT, LoDoCo2) show colchicine reduces cardiovascular events by 23–31% in patients with coronary artery disease
It works by blocking NLRP3 inflammasome activity and lowering IL-1β, IL-6 and CRP, rather than by lowering cholesterol
hsCRP testing helps identify patients whose residual risk is inflammation-driven and most likely to benefit from colchicine
It may offer precision protection for patients with CHIP mutations (notably TET2), where the inflammatory pathway is especially active
Low-dose colchicine (0.5mg daily) is generally well tolerated, with gastrointestinal upset the most common side effect

The Problem with Conventional Prevention

For the past half century, the story of heart disease prevention has been dominated by a single story: cholesterol. Lower the low-density lipoprotein (LDL), the thinking went, and you lower the risk.

Statins transformed cardiovascular medicine — and they remain essential. But a sobering truth persists: even patients on optimal lipid-lowering therapy continue to have heart attacks and strokes. Their cholesterol is controlled. Their blood pressure is managed. And yet, something else is still driving disease.

That something else is inflammation.

Inflammation: The Missing Piece

Over the past two decades, researchers have built an increasingly compelling case that chronic, low-grade inflammation is not merely a bystander in cardiovascular disease — it is a driver.

The CANTOS trial, published in 2017, provided landmark proof. It showed that canakinumab, a drug that specifically blocks the inflammatory molecule IL-1β, significantly reduced major cardiovascular events in patients with established coronary disease and elevated inflammatory markers — independent of any effect on cholesterol.¹

The message was clear: targeting inflammation, separately from lipids, can prevent heart attacks and strokes.

This opened the door for a much older and far cheaper drug to step into the spotlight.

Colchicine: From Ancient Remedy to Cardiovascular Medicine

Colchicine is not new. Derived from the autumn crocus (Colchicum autumnale), it has been used medicinally for thousands of years, primarily for gout and inflammatory joint conditions.

What is new is our understanding of why it works — and the realisation that its anti-inflammatory mechanisms map almost perfectly onto the pathways that drive heart disease.

How Colchicine Protects the Heart: The Science

Atherosclerosis — the build-up of fatty, inflammatory plaques inside artery walls — is fundamentally an inflammatory disease. The key molecular sequence runs as follows²:

Oxidised LDL and cholesterol crystals accumulate in artery walls, triggering immune cell activation
This activates the NLRP3 inflammasome — a protein complex inside immune cells that acts as an inflammatory alarm system
The NLRP3 inflammasome drives the release of IL-1β and IL-6
These inflammatory cytokines accelerate plaque growth, destabilise plaques (making them prone to rupture), and drive up C-reactive protein (CRP) — a blood marker of systemic inflammation

Colchicine disrupts this cascade at multiple points²:

It inhibits microtubule polymerisation, impairing the migration and activation of inflammatory immune cells (neutrophils and macrophages)
It blocks NLRP3 inflammasome assembly, preventing the cascade from being triggered in the first place
It reduces IL-1β and IL-6 production, turning down the inflammatory signal
It stabilises atherosclerotic plaques, reducing the risk of rupture — the event that causes most heart attacks
It impairs platelet activation and reduces selectin expression on inflamed vessel walls — further protecting against clot formation

In short, colchicine does not lower cholesterol. It targets the inflammatory fire that makes cholesterol dangerous.

The Clinical Evidence: What the Major Trials Show

The LoDoCo Trial (2013)³

The first major cardiovascular trial of colchicine enrolled 532 patients with stable coronary artery disease. Patients taking colchicine 0.5 mg daily experienced a 67% reduction in the composite endpoint of acute coronary syndrome, out-of-hospital cardiac arrest, or ischaemic stroke (hazard ratio 0.33) over a median follow-up of 36 months.

COLCOT Trial (2019)⁴

The ColOLchicine Cardiovascular Outcomes Trial enrolled 4,745 patients who had experienced a heart attack within the previous 30 days. Adding colchicine 0.5 mg daily to standard therapy reduced cardiovascular events by 23% compared to placebo (hazard ratio 0.77).

LoDoCo2 Trial (2020)⁵

The definitive confirmation came from LoDoCo2 — a randomised, double-blind, placebo-controlled trial of 5,522 patients with chronic coronary disease across Australia and the Netherlands. Colchicine 0.5 mg daily reduced the risk of cardiovascular death, spontaneous heart attack, ischaemic stroke, or ischaemia-driven coronary revascularisation by 31% (hazard ratio 0.69).

The magnitude of benefit was comparable to that of established secondary prevention therapies including lipid-lowering, blood pressure-lowering, and antithrombotic treatments.

Guideline Recognition

On the basis of this evidence, the 2021 European Society of Cardiology guidelines recommended that low-dose colchicine (0.5 mg once daily) may be considered for secondary cardiovascular prevention — particularly when other risk factors are insufficiently controlled or recurrent events occur on optimal therapy.6 Colchicine has since been incorporated into American College of Cardiology treatment guidelines for cardiovascular risk reduction in patients with chronic coronary disease.⁷

^{CRP: Your Window Into Inflammatory Risk}

C-reactive protein (CRP) — and in particular high-sensitivity CRP (hsCRP) — is a blood test that measures the level of systemic inflammation in the body. It is one of the most clinically accessible tools for identifying individuals whose cardiovascular risk is driven by inflammation rather than, or in addition to, elevated lipids.

A meta-analysis of randomised controlled trials confirmed that colchicine significantly reduces serum CRP, consistent with its upstream inhibition of the IL-1β/NLRP3 inflammasome-driven inflammatory pathway.⁸

Critically, other trials have shown that lowering CRP to below 2 mg/L is independently associated with significant cardiovascular benefit. ⁹The JUPITER trial demonstrated that rosuvastatin reduced CRP by 37% alongside a reduction in cardiovascular event rates, even in patients without elevated cholesterol.¹⁰

This means that hsCRP serves a dual purpose in the colchicine era: it identifies patients most likely to benefit from anti-inflammatory therapy, and it provides a measurable target to guide treatment.

The CHIP Connection: Precision Anti-Inflammatory Prevention

Here is where the story becomes particularly compelling for those interested in precision medicine and preventive cardiology.
As we explored in our previous blog on Clonal Haematopoiesis (CH), certain age-acquired somatic mutations in blood cells dramatically amplify cardiovascular risk through an inflammatory mechanism. Mutant immune cells exhibit loss of normal inflammatory restraint, producing excessive IL-1β and IL-6, and driving accelerated atherosclerosis through inflammasome activation.

This is precisely the same pathway that colchicine targets.

In mouse models, colchicine has been shown to prevent accelerated atherosclerosis — directly blunting the heightened cardiovascular risk conferred by TET2 mutations by suppressing IL-1β overproduction.

Human data are also emerging: colchicine shows a protective trend against myocardial infarction in human cohorts with TET2 mutations, positioning it as a potential precision therapy for this specific high-risk group.

Furthermore, expert consensus frameworks for CHIP now recommend that when hsCRP is elevated in a CHIP patient, anti-inflammatory agents — including colchicine, as per cardiology recommendations — should be considered.^11,12

This creates a powerful and emerging clinical framework:

Test for CHIP → identify mutation-driven inflammatory cardiovascular risk
Measure hsCRP → quantify active systemic inflammation
Consider colchicine → target the shared pathways driving both

Who Might Benefit From Colchicine?

Based on the current evidence, colchicine for cardiovascular prevention is most clearly indicated in:

Patients with established coronary artery disease (post-myocardial infarction or chronic coronary disease) in whom standard risk factors are optimised but residual inflammatory risk remains
Patients with elevated hsCRP despite lipid and blood pressure management, suggesting inflammation as a primary residual driver
Patients with CHIP mutations — particularly TET2 — in whom the NLRP3-driven inflammatory phenotype is both biologically specific and potentially colchicine-responsive
Patients with recurrent cardiovascular events on optimal medical therapy, where an inflammatory aetiology is suspected

Safety and Tolerability

Colchicine is generally well tolerated at the low doses used in cardiovascular prevention (0.5 mg once daily). The most common side effect is gastrointestinal upset — diarrhoea, nausea, or abdominal discomfort — which leads some patients to discontinue therapy but is usually manageable.

Long-term use of low-dose colchicine has not been associated with increased risks of cancer, sepsis, cytopenia, muscle toxicity, or changes in kidney function.¹³

One signal of note from LoDoCo2 was a numerically higher rate of non-cardiovascular mortality in the colchicine group compared to placebo (hazard ratio 1.51), though this did not reach statistical significance, and hospitalisations for infections and pneumonia were similar between groups.⁵This remains an area of ongoing monitoring in longer-term follow-up studies.

Important practical considerations include:

Dose reduction required in significant kidney or liver impairment
Drug interactions with strong CYP3A4 or P-glycoprotein inhibitors (including certain statins and some antibiotics) can increase colchicine toxicity
Not currently indicated for primary prevention in individuals without established cardiovascular disease or a clearly elevated inflammatory risk

The Bigger Picture: From Cholesterol to Inflammation

The emergence of colchicine as a cardiovascular therapy represents something more than just a new drug for an established indication. It represents a fundamental shift in how we understand and prevent heart disease.

For decades, cardiovascular risk has been framed almost entirely in metabolic terms — cholesterol, blood pressure, blood glucose. These remain critical. But the evidence now makes clear that chronic inflammation is an independent and modifiable risk factor for cardiovascular events — one that is not captured by standard lipid panels, and one that requires its own assessment and treatment strategy.

The CHIP-CRP-colchicine axis is perhaps the most exciting frontier in this space. It offers, for the first time, the possibility of precision anti-inflammatory cardiovascular prevention — identifying specific individuals (those with TET2-mutant CHIP and elevated hsCRP) who carry a biologically defined inflammatory phenotype, and targeting it with a safe, inexpensive, well-established drug.

We are entering an era in which a truly comprehensive cardiovascular risk assessment will include not just lipids and blood pressure, but inflammatory markers and genetic profiling of blood cells — guiding targeted therapies that address the full spectrum of risk.

Colchicine, an ancient remedy rediscovered, may be one of the most important tools in that new toolkit.

Dr Tim Trodd

Family Medicine, Functional Medicine, General Practice

MBBS (London)
DCH (London)
DRCOG (UK)
MRCGP (UK)
FHKAM (Family Medicine)

View Profile View Reports & Publications

Health Articles by Dr Tim Trodd

Interviews

References

Ridker, P.M. et al. (2017). ‘Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS).’ New England Journal of Medicine, 377, pp. 1119–1131.
Li, Y. et al. (2021). ‘Anti-inflammatory mechanisms and research progress of colchicine in atherosclerotic therapy.’ Journal of Cellular and Molecular Medicine, 25, pp. 8087–8094.
Nidorf, S.M., Eikelboom, J.W., Budgeon, C.A. and Thompson, P.L. (2013). ‘Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease.’ Journal of the American College of Cardiology, 61(4), pp. 404–410.
Tardif, J.C., Kouz, S., Waters, D.D. et al. (2019). ‘Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.’ New England Journal of Medicine, 381(26), pp. 2497–2505. Available at: https://doi.org/10.1056/NEJMoa1912388.
Nidorf, S.M. et al. (2020). ‘Colchicine in Patients with Chronic Coronary Disease (LoDoCo2).’ New England Journal of Medicine, 383, pp. 1838–1847.
Visseren, F.L.J., Mach, F., Smulders, Y.M. et al. (2021). ‘2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.’ European Heart Journal, 42(34), pp. 3227–3337.
Virani, S., Newby, L., Arnold, S. et al. (2023). ‘2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.’ Journal of the American College of Cardiology, 82(9), pp. 833–955.
Li, H.Y., Cheriyan, J., Chan, T.K. et al. (2026). ‘Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials including 31,397 Subjects Worldwide.’ American Journal of Cardiovascular Drugs, 26, pp. 107–120.
Asher, J. and Houston, M. (2007). ‘Statins and C-Reactive Protein Levels.’ The Journal of Clinical Hypertension, 9, pp. 622–628. Available at: https://doi.org/10.1111/j.1524-6175.2007.06639.x.
Ridker, P., Danielson, E., Fonseca, F. et al. (2008). ‘Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein.’ New England Journal of Medicine, 359(21), pp. 2195–2207. Available at: https://doi.org/10.1056/NEJMoa0807646.
Rhee, J.W., Bolton, K.L., Gupta, D. et al. (2026). ‘Clonal Hematopoiesis and Its Cardiovascular Implications: A Scientific Statement From the American Heart Association.’ Circulation, 153(11), pp. e940–e952. Available at: https://doi.org/10.1161/CIR.0000000000001404.
Anastasiou, I.A., Kounatidis, D., Vallianou, N.G., Rebelos, E., Karampela, I. and Dalamaga, M. (2026). ‘Clonal Hematopoiesis of Indeterminate Potential and Cardiometabolic Disease: Challenges, Controversies and Future Perspectives.’ International Journal of Molecular Sciences, 27(1), p. 233. Available at: https://doi.org/10.3390/ijms27010233.
Samuel, M., Berry, C., Dubé, M.P., Koenig, W., López-Sendón, J., Maggioni, A.P., Pinto, F.J., Roubille, F. and Tardif, J.C. (2025). ‘Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.’ European Heart Journal, 46(26), pp. 2552–2563.